

Denis Viglietti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8629158/publications.pdf>

Version: 2024-02-01

17
papers

1,311
citations

567281

15
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

1901
citing authors

#	ARTICLE	IF	CITATIONS
1	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 293-304.	6.1	244
2	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. <i>BMJ, The</i> , 2015, 351, h3557.	6.0	146
3	Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. <i>JAMA Internal Medicine</i> , 2019, 179, 1365.	5.1	125
4	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. <i>Kidney International</i> , 2019, 96, 189-201.	5.2	117
5	Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 702-715.	6.1	111
6	Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 620-635.	6.1	94
7	T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. <i>American Journal of Transplantation</i> , 2018, 18, 377-390.	4.7	76
8	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002572.	8.4	76
9	Biomarkers of IgA vasculitis nephritis in children. <i>PLoS ONE</i> , 2017, 12, e0188718.	2.5	63
10	Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. <i>American Journal of Transplantation</i> , 2019, 19, 1972-1988.	4.7	60
11	Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. <i>Kidney International</i> , 2017, 92, 729-742.	5.2	43
12	Determinants and Outcomes of Accelerated Arteriosclerosis. <i>Circulation Research</i> , 2015, 117, 470-482.	4.5	41
13	Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. <i>Kidney International</i> , 2018, 94, 773-787.	5.2	38
14	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. <i>Nephrology Dialysis Transplantation</i> , 2017, 33, 1579-1590.	0.7	37
15	Perirenal fluid collections and monoclonal gammopathy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 448-449.	0.7	18
16	Evidence for an important role of both complement-binding and noncomplement-binding donor-specific antibodies in renal transplantation. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 433-440.	1.6	11
17	Recognition of i-IF/TA as a component of the T cell-mediated rejection spectrum: Unselected population approach vs random case selection. <i>American Journal of Transplantation</i> , 2018, 18, 771-772.	4.7	3